MIM
RCKT icon

MetLife Investment Management’s Rocket Pharmaceuticals RCKT Stock Holding History

MetLife Investment Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Sell
45,656
-895
-2% -$2.98K ﹤0.01% 2544
2026
Q1 		$167K Buy
46,551
+13,071
+39% +$51.9K ﹤0.01% 2317
2025
Q4 		$118K Sell
33,480
-12,825
-28% -$43.9K ﹤0.01% 2535
2025
Q3 		$151K Buy
46,305
+446
+1% +$1.41K ﹤0.01% 2470
2025
Q2 		$112K Buy
45,859
+1
+0% +$5 ﹤0.01% 2480
2025
Q1 		$306K Buy
45,858
+5,371
+13% +$53.1K ﹤0.01% 1964
2024
Q4 		$509K Buy
40,487
+2,986
+8% +$44.9K ﹤0.01% 1788
2024
Q3 		$693K Hold
37,501
– – ﹤0.01% 1601
2024
Q2 		$807K Buy
37,501
+4,498
+14% +$103K ﹤0.01% 1461
2024
Q1 		$889K Hold
33,003
– – 0.01% 1364
2023
Q4 		$989K Buy
33,003
+4,097
+14% +$90.4K 0.01% 1299
2023
Q3 		$592K Hold
28,906
– – ﹤0.01% 1526
2023
Q2 		$574K Buy
28,906
+720
+3% +$14.5K ﹤0.01% 1601
2023
Q1 		$483K Hold
28,186
– – ﹤0.01% 1667
2022
Q4 		$552K Buy
28,186
+5,211
+23% +$96K ﹤0.01% 1578
2022
Q3 		$367K Hold
22,975
– – ﹤0.01% 1863
2022
Q2 		$316K Hold
22,975
– – ﹤0.01% 1986
2022
Q1 		$364K Buy
22,975
+8,301
+57% +$143K ﹤0.01% 1973
2021
Q4 		$320K Hold
14,674
– – ﹤0.01% 1771
2021
Q3 		$439K Hold
14,674
– – ﹤0.01% 1596
2021
Q2 		$650K Hold
14,674
– – 0.01% 1421
2021
Q1 		$651K Hold
14,674
– – 0.01% 1377
2020
Q4 		$805K Hold
14,674
– – 0.01% 1229
2020
Q3 		$335K Hold
14,674
– – ﹤0.01% 1574
2020
Q2 		$307K Hold
14,674
– – ﹤0.01% 1641
2020
Q1 		$205K Hold
14,674
– – ﹤0.01% 1684
2019
Q4 		$334K Hold
14,674
– – ﹤0.01% 1676
2019
Q3 		$171K Hold
14,674
– – ﹤0.01% 2030
2019
Q2 		$220K Sell
14,674
-16,772
-53% -$293K ﹤0.01% 1975
2019
Q1 		$552K Buy
31,446
+20,964
+200% +$331K ﹤0.01% 1997
2018
Q4 		$155K Hold
10,482
– – ﹤0.01% 2053
2018
Q3 		$258K Buy
+10,482
New +$227K ﹤0.01% 1945

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

MetLife Investment Management's RCKT Position: Q2 2026 in Review

MetLife Investment Management reduced its Rocket Pharmaceuticals (RCKT) stake by 1.9% in Q2 2026, selling an estimated $2.98K and leaving 45,656 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #2544.

MetLife Investment Management first reported a position in RCKT in Q3 2018 and has held it in 32 quarters since. The position peaked at $989K in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • MetLife Investment Management held 45,656 shares of Rocket Pharmaceuticals worth $156K as of Q2 2026.
  • MetLife Investment Management sold 895 Rocket Pharmaceuticals shares in Q2 2026, an estimated $2.98K.
  • Rocket Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2544 holding.
  • MetLife Investment Management first reported a position in Rocket Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • MetLife Investment Management's Rocket Pharmaceuticals position peaked at $989K in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.